Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8286 | 1.00 | USP2 (0.58) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL1225127 | 1.00 | USP2 (0.58) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL587550 | 1.00 | USP2 (0.58) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL2220355 | 0.98 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL14653343 | 0.98 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| Ammonia Solution, Strong SCHEMBL18035416 | 0.98 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| Hydrochloric Acid SCHEMBL1904026 | 0.98 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| Hydrochloric Acid SCHEMBL4141237 | 0.98 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL132585 | 0.98 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL | |
| SCHEMBL2934532 | 0.98 | USP2 (0.56) | USP2SMN1; SMN2MAPK1HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024235128-A9 | ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2024235132-A9 | COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2025087229-A1 | LIGAND COMPOUND OF QUINOLINE STRUCTURE, RADIOACTIVE OR NON-RADIOACTIVE MARKER, AND USE | 四川科伦博泰生物医药股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025087466-A2 | LIGAND COMPOUND OF QUINOLINE STRUCTURE, AND RADIOACTIVE OR NON-RADIOACTIVE MARKER THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2024235128-A1 | ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| WO-2024235132-A1 | COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| EP-4087621-A1 | MACROCYCLIC CHELATES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2022-11-16 | — | — | EP | disclosed |
| CN-115243729-A | Macrocyclic chelates and their use | 融合制药公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20210395281-A1 | MACROCYCLIC CHELATES AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| US-20210395281-A1 | MACROCYCLIC CHELATES AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| EP-2495563-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | Fujifilm RI Pharma Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | FUJIFILM RI PHARMA CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395281-A1 | MACROCYCLIC CHELATES AND USES THEREOF | PAICS, CLTC, CLTB | USP2 2974/4885SMN1; SMN2 2853/4885MAPK1 4841/4885 |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | NISCH, CNDP2, MYADM | USP2 2163/4885SMN1; SMN2 2683/4885MAPK1 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.